logo
  

AbbVie: FDA To Review BLA For Epcoritamab - Quick Facts

AbbVie (ABBV) announced the FDA has accepted for priority review the Biologics License Application for epcoritamab, an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy. Epcoritamab is being co-developed by AbbVie and Genmab as part of oncology collaboration.

The company noted that its application is supported by data from EPCORE NHL-1 Phase 1/2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma, including large B-cell lymphoma.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity... Chinese electric vehicle manufacturer Xpeng announced the launch of its two latest smart EV models for a number of European markets. Xpeng G9 flagship SUV, and the new P7 sports sedan are now available for order in Denmark, Norway, the Netherlands, and Sweden. Both models are on show at eCar Expo 2023 in Stockholm from February 3 to 5.
Follow RTT